Neuronal ceroid lipofuscinosis type 1 · PPT1 deficiency · Ceroid-Lipofuszinose Typ 1 · Canine NCL 1 · PPT1-related Neuronal Ceroid Lipofuscinosis · CLN1 Lysosomal Storage Disease · PPT1-associated retinal dystrophy
Neuronal ceroid lipofuscinosis type 1 (NCL1) is an inherited metabolic disorder that affects the nervous system. It is classified as a lysosomal storage disease, which means the cells' internal recycling centers (lysosomes) cannot properly break down waste. This leads to a harmful buildup of cellular debris in the nerve cells of the brain and eyes, causing progressive damage.
Symptoms typically become noticeable when a dog is between 1 and 2 years of age. Owners may observe progressive vision loss, changes in behavior, difficulty coordinating movements, and seizures.
There is no cure for NCL1, and treatment focuses entirely on supportive, palliative care to keep the dog comfortable. Managing symptoms and maintaining quality of life typically costs between 1,000 and 4,000 EUR.
Estimated range of typical treatment cost. Actual cost depends on severity, clinic and region.
More conditions affecting the Head / nervous system.